The recent approval of Eli Lilly and Company’s Zepbound (tirzepatide) for obesity means two highly effective incretin drugs are now available for obesity. Lilly believes it can supply Zepbound in large quantities from the off, besting Novo Nordisk A/S which has been unable to make Wegovy (semaglutide 2.4mg injection) in sufficient amounts to meet demand.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?